Rilmenidine
As of the edition of 20 October 2026, Rilmenidine is a small molecule: marketed, first approved in 1987 (FR); acts on NISCH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Hyperium
- First approved
- 23 April 1987 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Servier
- Registered trials
- 1, 1 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NISCH | Nischarin | Q9Y2I1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 1 |